CN108368095B - 作为sap消耗剂的d-脯氨酸衍生物 - Google Patents

作为sap消耗剂的d-脯氨酸衍生物 Download PDF

Info

Publication number
CN108368095B
CN108368095B CN201680073108.0A CN201680073108A CN108368095B CN 108368095 B CN108368095 B CN 108368095B CN 201680073108 A CN201680073108 A CN 201680073108A CN 108368095 B CN108368095 B CN 108368095B
Authority
CN
China
Prior art keywords
sap
compound
disease
formula
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680073108.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108368095A (zh
Inventor
A.丹尼斯
O.米尔格特
J.托姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN108368095A publication Critical patent/CN108368095A/zh
Application granted granted Critical
Publication of CN108368095B publication Critical patent/CN108368095B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680073108.0A 2015-10-27 2016-10-25 作为sap消耗剂的d-脯氨酸衍生物 Expired - Fee Related CN108368095B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518950.9 2015-10-27
GBGB1518950.9A GB201518950D0 (en) 2015-10-27 2015-10-27 Compound
PCT/EP2016/075632 WO2017072099A1 (en) 2015-10-27 2016-10-25 D-proline derivatives as sap depleting agent

Publications (2)

Publication Number Publication Date
CN108368095A CN108368095A (zh) 2018-08-03
CN108368095B true CN108368095B (zh) 2021-06-08

Family

ID=55130261

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073108.0A Expired - Fee Related CN108368095B (zh) 2015-10-27 2016-10-25 作为sap消耗剂的d-脯氨酸衍生物

Country Status (12)

Country Link
US (1) US10328052B2 (enExample)
EP (1) EP3368532B1 (enExample)
JP (2) JP6789288B2 (enExample)
KR (1) KR20180067559A (enExample)
CN (1) CN108368095B (enExample)
AU (1) AU2016345462A1 (enExample)
BR (1) BR112018008582A2 (enExample)
CA (1) CA3002710A1 (enExample)
ES (1) ES2781550T3 (enExample)
GB (1) GB201518950D0 (enExample)
RU (1) RU2018119120A (enExample)
WO (1) WO2017072099A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178912C (zh) * 1995-06-07 2004-12-08 吉尔福特药品有限公司 旋转异构酶活性的小分子抑制剂
CN100357270C (zh) * 1997-10-31 2007-12-26 弗·哈夫曼-拉罗切有限公司 D－脯氨酸衍生物
WO2009143153A1 (en) * 2008-05-23 2009-11-26 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine h3 receptor
CN106459016A (zh) * 2014-04-29 2017-02-22 葛兰素史密斯克莱知识产权发展有限公司 1,1’‑(1,6‑二氧代‑1,6‑己二基)双‑d‑脯氨酸的前药

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178912C (zh) * 1995-06-07 2004-12-08 吉尔福特药品有限公司 旋转异构酶活性的小分子抑制剂
CN100357270C (zh) * 1997-10-31 2007-12-26 弗·哈夫曼-拉罗切有限公司 D－脯氨酸衍生物
WO2009143153A1 (en) * 2008-05-23 2009-11-26 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine h3 receptor
CN106459016A (zh) * 2014-04-29 2017-02-22 葛兰素史密斯克莱知识产权发展有限公司 1,1’‑(1,6‑二氧代‑1,6‑己二基)双‑d‑脯氨酸的前药

Also Published As

Publication number Publication date
RU2018119120A (ru) 2019-11-28
EP3368532B1 (en) 2020-01-15
US10328052B2 (en) 2019-06-25
CA3002710A1 (en) 2017-05-04
KR20180067559A (ko) 2018-06-20
JP2018531967A (ja) 2018-11-01
CN108368095A (zh) 2018-08-03
GB201518950D0 (en) 2015-12-09
US20190060274A1 (en) 2019-02-28
JP7053762B2 (ja) 2022-04-12
JP2021035963A (ja) 2021-03-04
BR112018008582A2 (pt) 2018-10-30
ES2781550T3 (es) 2020-09-03
WO2017072099A1 (en) 2017-05-04
JP6789288B2 (ja) 2020-11-25
AU2016345462A1 (en) 2018-04-26
EP3368532A1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
EP3980011B1 (en) Inhibitors of sarm1
AU2018216040A1 (en) OGA inhibitor compounds
US9737505B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
WO2023165459A1 (en) Compounds as sars-cov-2 inhibitors
WO2023088418A1 (en) Compounds as sars-cov-2 inhibitors
US10597385B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
KR20190025545A (ko) 특정 단백질 키나제 억제제
EP2523552B1 (en) Pyrazolo[1,5-a]pyrimidines as mark inhibitors
JP7053762B2 (ja) Ｓａｐ枯渇剤としてのｄ－プロリン誘導体
JP2021527668A (ja) Ｏｇａ阻害化合物
WO2023004138A1 (en) Agonists of tyro3 as protection against podocyte injury in kidney glomerular disease
JP2022537291A (ja) ヘテロ環式誘導体及びその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210608

CF01 Termination of patent right due to non-payment of annual fee